Skip to content
Canine PeptideResearch peptides

Peptides for Australian Shepherd tendon and ligament injury

The short answer

Australian Shepherds carry an elevated predisposition to tendon and ligament injury. The compounds investigated for it are BPC-157, TB-500, MGF. At a typical Australian Shepherd weight of 16–32 kg (35–71 lb), this breed falls in the medium breed dosing class. Critically, this breed carries a genetic trait that changes what is safe: MDR1 (ABCB1) mutation risk — genetic testing required before ivermectin

The Australian Shepherd-specific risk

⚠ MDR1 (ABCB1) mutation risk — genetic testing required before ivermectin

This breed carries a meaningful frequency of the MDR1 gene mutation, which prevents the drug-efflux protein at the blood-brain barrier from clearing ivermectin out of the central nervous system. Affected dogs develop neurotoxicity at doses other dogs tolerate without difficulty, and at the investigational oncology doses discussed on this site that reaction can be fatal. A cheek-swab test through Washington State University or a commercial laboratory settles the question and must be done before the first dose.

Tendon and ligament injury in Australian Shepherds

Tendon and ligament tissue has a poor blood supply, which is the reason these injuries heal slowly and recur so readily. Repair tissue is also mechanically inferior to the original, so an inadequately rehabilitated injury tends to become a chronic one. This is where the largest share of the preclinical peptide literature sits — BPC-157's tendon-to-bone healing work and TB-500's cell migration research both target exactly this problem. It remains preclinical, but it is the most mechanistically coherent application on this site.

Dosing at Australian Shepherd body weight

Calculated for a 24 kg (53 lb) dog — the midpoint of the typical range for this breed.

CompoundDose at 24 kgFrequencyEvidence
BPC-15748–240 mcgOnce dailyEmerging evidence
TB-5002.4–6 mgWeekly TOTAL — split into 1-2 injections/week for a 2-4 week loading phase, then about half that weekly total for maintenanceEmerging evidence
MGF48–120 mcgDaily or every other dayPreliminary / in vitro only

Weigh your dog rather than using a breed average — an individual Australian Shepherd can sit well outside the typical range. Use the dose calculator for an exact figure.

Common questions

What peptides are used for tendon and ligament injury in Australian Shepherds?+

BPC-157, TB-500, MGF are investigated for tendon and ligament injury. Note that Australian Shepherds carry a specific genetic consideration: MDR1 (ABCB1) mutation risk — genetic testing required before ivermectin

How much should a Australian Shepherd be given?+

Australian Shepherds typically weigh 16–32 kg (35–71 lb), placing them in the medium breed class. BPC-157: approximately 48–240 mcg at 24 kg. TB-500: approximately 2.4–6 mg at 24 kg. MGF: approximately 48–120 mcg at 24 kg. Weigh your dog rather than relying on a breed average.

Are Australian Shepherds more prone to tendon and ligament injury?+

Yes. Australian Shepherds carry an elevated predisposition to tendon and ligament injury. Strains, partial tears, and chronic tendinopathies in working, sporting, and active dogs.

References

  1. 1.CANINE STUDYHe L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588717
  2. 2.CANINE STUDYXu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
  3. 3.Vasireddi N, Nguyen HH, Ahmed WA, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. PMID 40756949
  4. 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
  5. 5.Józwiak M, Bauer M, Kamysz W, Kleczkowska P Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals, 2025. PMID 40005999
  6. 6.Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 2026. PMID 41476424
  7. 7.Kleinman HK, Sosne G Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones, 2016. PMID 27450738
  8. 8.Philp D, Kleinman HK Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Annals of the New York Academy of Sciences, 2010. PMID 20536453
  9. 9.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 2012. PMID 22074294
  10. 10.Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma. Journal of Chromatography A, 2012. PMID 23084823
  11. 11.Delcourt V, Loup B, Bailly-Chouriberry L, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and unapproved drugs. Drug Testing and Analysis, 2023. PMID 36482504
  12. 12.Goldspink G Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology, 2005. PMID 16024511
  13. 13.Kandalla PK, Goldspink G, Butler-Browne G, Mouly V Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mechanisms of Ageing and Development, 2011. PMID 21354439

Other conditions Australian Shepherds are predisposed to: Hip dysplasia.

Where to source research peptides

Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.

Visit Pet & Peps Research →How to evaluate a supplier

Educational information — not veterinary medical advice

Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.